Research map: A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma

Back to the article

Papers in this map

  1. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff · Pablo Cingolani · 2012 · 13015 citations · Cited by this paper
  2. Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma · 2026 · Related
  3. Calreticulin exposure dictates the immunogenicity of cancer cell death · Michel Obéid · 2006 · 3205 citations · Cited by this paper
  4. High KPNA2 expression predicts poor prognosis in pathological T4 colorectal cancer by importing c-Myc into the nucleus to suppress p53-dependent p21 expression · 2026 · Related
  5. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors · Stephen B. Willingham · 2012 · 1705 citations · Cited by this paper
  6. Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial · 2026 · Related
  7. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses · Pierre Bruhns · 2008 · 1500 citations · Cited by this paper
  8. Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells · 2026 · Related
  9. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology · Margaret von Mehren · 2022 · 1189 citations · Cited by this paper
  10. Interpreting the adverse esophageal and colorectal findings in the Cancer Risk in Vegetarians Consortium · 2026 · Related
  11. Doxorubicin Cardiomyopathy · Kanu Chatterjee · 2009 · 1085 citations · Cited by this paper
  12. AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma · 2026 · Related
  13. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ · Alessandro Gronchi · 2021 · 1059 citations · Cited by this paper
  14. Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies · 2026 · Related
  15. CD47 blockade triggers T cell–mediated destruction of immunogenic tumors · Xiaojuan Liu · 2015 · 783 citations · Cited by this paper
  16. Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis · 2026 · Related
  17. Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project · Charles A. Stiller · 2012 · 695 citations · Cited by this paper
  18. Signatures of micropeptides encoded by lncRNAs in cancer progression and metastasis · 2026 · Related
  19. Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins. · Eric J. Brown · 1990 · 416 citations · Cited by this paper
  20. Can national lung cancer screening programs be implemented without exacerbating social disparities? · 2026 · Related
  21. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma · Ian Robert Judson · 2001 · 393 citations · Cited by this paper
  22. Targeting CD47 for cancer immunotherapy · Zhongxing Jiang · 2021 · 362 citations · Cited by this paper
  23. Integrative genomic and transcriptomic analysis of leiomyosarcoma · Priya Chudasama · 2018 · 315 citations · Cited by this paper
  24. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas · William D. Tap · 2020 · 312 citations · Cited by this paper
  25. Macrophages are critical effectors of antibody therapies for cancer · Kipp Weiskopf · 2015 · 300 citations · Cited by this paper
  26. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding · Penka S. Petrova · 2016 · 288 citations · Cited by this paper
  27. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma · Badreddin Edris · 2012 · 261 citations · Cited by this paper
  28. Soft Tissue and Uterine Leiomyosarcoma · Suzanne George · 2017 · 247 citations · Cited by this paper
  29. Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies · Stephen Maxted Ansell · 2021 · 207 citations · Cited by this paper
  30. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma · David Schoenfeld · 1982 · 174 citations · Cited by this paper
  31. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival · Antoîne Italiano · 2011 · 165 citations · Cited by this paper
  32. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3 · William J. Mawby · 1994 · 149 citations · Cited by this paper
  33. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group · Lorenzo D’Ambrosio · 2020 · 147 citations · Cited by this paper
  34. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma · Seth M. Pollack · 2020 · 145 citations · Cited by this paper
  35. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study · Nehal J Lakhani · 2021 · 138 citations · Cited by this paper
  36. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial · Patricia Pautier · 2022 · 136 citations · Cited by this paper
  37. UK guidelines for the management of soft tissue sarcomas · Andrew J Hayes · 2024 · 125 citations · Cited by this paper
  38. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome · Nicolas Penel · 2011 · 118 citations · Cited by this paper
  39. Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma · Patricia Pautier · 2024 · 88 citations · Cited by this paper

Source: OpenAlex (CC0)